164 related articles for article (PubMed ID: 26239337)
1. No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.
Brath JM; Grill S; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
J Urol; 2016 Feb; 195(2):343-8. PubMed ID: 26239337
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
4. Familial prostate cancer: a different disease?
Kupelian PA; Klein EA; Witte JS; Kupelian VA; Suh JH
J Urol; 1997 Dec; 158(6):2197-201. PubMed ID: 9366343
[TBL] [Abstract][Full Text] [Related]
5. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
Liesenfeld L; Kron M; Gschwend JE; Herkommer K
J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
9. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
10. The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes.
Mikel Hubanks J; Boorjian SA; Frank I; Gettman MT; Houston Thompson R; Rangel LJ; Bergstralh EJ; Jeffrey Karnes R
Urol Oncol; 2014 Jan; 32(1):26.e1-7. PubMed ID: 23395235
[TBL] [Abstract][Full Text] [Related]
11. Obesity and long-term survival after radical prostatectomy.
Chalfin HJ; Lee SB; Jeong BC; Freedland SJ; Alai H; Feng Z; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
J Urol; 2014 Oct; 192(4):1100-4. PubMed ID: 24769031
[TBL] [Abstract][Full Text] [Related]
12. Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases.
Kates M; Sopko NA; Han M; Partin AW; Epstein JI
J Urol; 2016 Feb; 195(2):337-42. PubMed ID: 26264998
[TBL] [Abstract][Full Text] [Related]
13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
14. A Family History of Lethal Prostate Cancer and Risk of Aggressive Prostate Cancer in Patients Undergoing Radical Prostatectomy.
Raheem OA; Cohen SA; Parsons JK; Palazzi KL; Kane CJ
Sci Rep; 2015 Jun; 5():10544. PubMed ID: 26112134
[TBL] [Abstract][Full Text] [Related]
15. Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup.
Moschini M; Sharma V; Zattoni F; Boorjian SA; Frank I; Gettman MT; Thompson RH; Tollefson MK; Kwon ED; Karnes RJ
J Urol; 2016 Jun; 195(6):1773-8. PubMed ID: 26723866
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
17. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
18. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
19. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
20. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.
Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G
Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
